Trial Profile
A Phase Ib/II Dose-finding Study of DDFPe in Patients With Acute Ischemic Stroke
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 27 Sep 2021
Price :
$35
*
At a glance
- Drugs Perflenapent (Primary)
- Indications Stroke
- Focus Adverse reactions
- 08 Feb 2019 According to a NuvOx Pharma media release, positive results from this study have been published at the International Stroke Conference.
- 08 Feb 2019 Results presented in a NuvOx Pharma media release.
- 10 Aug 2018 Status changed from recruiting to completed.